Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 238

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST)

Open access
Arendrup, M.C., Friberg, N., Mares, M., Kahlmeter, G., Meletiadis, J., Guinea, J., Arendrup, M.C., Meletiadis, J., Guinea, J., Friberg, N., Mares, M., Kahlmeter, G., Andersen, C.T., Arikan-Akdagli, S., Barchiesi, F., Chryssanthou, E., Hamal, P., Järv, H., Klimko, N., Kurzai, O., Lagrou, K., Lass-Flörl, C., Matos, T., Muehlethaler, K., Rogers, T.R., Velegraki, A., Arikan, S. · 2020 · Clinical Microbiology and Infection

Abstract

BACKGROUND EUCAST has revised the definition of the susceptibility category "I" from "Intermediate" to "Susceptible, Increased exposure". This implies that "I" can be used where the drug-concentration at the site of infection is high, either because of dose escalation or through other means to ensure efficacy. Consequently, "I" is no longer used as a buffer-zone to prevent technical factors from causing misclassifications and discrepancies in interpretations. Instead, an "Area of Technical Uncertainty" (ATU) has been introduced for MICs that cannot be categorised without additional information as a warning to the laboratory that decision on how to act has to be made. To implement these changes, the EUCAST-AFST (Subcommittee on Antifungal Susceptibility Testing) reviewed all, and revised some, clinical antifungal breakpoints. OBJECTIVES To present an overview of the current antifungal breakpoints and supporting evidence behind the changes. SOURCES This document is based on the 10 recently updated EUCAST rationale documents, clinical breakpoint and breakpoint-ECOFF documents. CONTENT The following breakpoints (in mg/L) have been revised or established for Candida species: micafungin against C. albicans (ATU=0.03); amphotericin B (S≤/>R=1/1), fluconazole (S≤/>R=2/4), itraconazole (S≤/>R=0.06/0.06), posaconazole (S≤/>R=0.06/0.06) and voriconazole (S≤/>R=0.06/0.25) against C. dubliniensis; fluconazole against C. glabrata (I≤/>R=16/32); and anidulafungin (S≤/>R=4/4) and micafungin (S≤/>R=2/2) against C. parapsilosis. For Aspergillus, new or revised breakpoints include: itraconazole (ATU=2) and isavuconazole against A. flavus (S≤/>R=1/2, ATU=2); amphotericin B (S≤/>R=1/1), isavuconazole (S≤/>R=1/2, ATU=2), itraconazole (S≤/>R=1/1, ATU=2), posaconazole (ATU=0.25) and voriconazole (S≤/>R=1/1, ATU=2) against A. fumigatus; itraconazole (S≤/>R=1/1, ATU=2) and voriconazole (S≤/>R=1/1, ATU=2) against A. nidulans; amphotericin B against A. niger (S≤/>R=1/1); and itraconazole (S≤/>R=1/1, ATU=2) and posaconazole (ATU=0.25) against A. terreus. IMPLICATIONS EUCAST-AFST has released 10 new documents summarising existing and new breakpoints and MIC-ranges for control strains. A failure to adopt the breakpoint changes may lead to misclassifications and sub-optimal or inappropriate therapy of patients with fungal infections.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cmi.2020.06.007

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 238

Metadata

Authors
Arendrup, M. C., Friberg, N., Mares, M., Kahlmeter, G., Meletiadis, J., Guinea, J., Arendrup, M. C., Meletiadis, J., Guinea, J., Friberg, N., Mares, M., Kahlmeter, G., Andersen, C. T., Arikan-Akdagli, S., Barchiesi, F., Chryssanthou, E., Hamal, P., Järv, H., Klimko, N., Kurzai, O., Lagrou, K., Lass-Flörl, C., Matos, T., Muehlethaler, K., Rogers, T. R., Velegraki, A., & Arikan, S.
Venue
Clinical Microbiology and Infection
Publisher
Elsevier BV
Published
2020-11
Volume
26
Issue
11
Pages
1464-1472
ISSN
1198-743X (ISSN-L)
OpenAlex
W3036059246
Cited by
238
References
18
FWCI
4.35
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST). https://app.cochat.ai/papers/10.1016/j.cmi.2020.06.007
The paper
Arendrup, M. C., Friberg, N., Mares, M., Kahlmeter, G., Meletiadis, J., Guinea, J., Arendrup, M. C., Meletiadis, J., Guinea, J., Friberg, N., Mares, M., Kahlmeter, G., Andersen, C. T., Arikan-Akdagli, S., Barchiesi, F., Chryssanthou, E., Hamal, P., Järv, H., Klimko, N., . . . Arikan, S. (2020). How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST). Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2020.06.007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.